楽園主義に向かって進む!〜Head toward Paradism...弥勒菩薩ラエルの教えと共に



Mechai Viravaidya
From Wikipedia, the free encyclopedia

Mechai Viravaidya (born January 17, 1941, Thai: มีชัย วีระไวทยะ) is a former politician and activist in Thailand who has popularized condoms in that country.[1]

Since the 1970s, Mechai has been affectionately known as "Mr. Condom", and in that time condoms are referred to as "mechais" in Thailand[2] From the time that he began his work, the average number of children in Thai families has reduced from 7 to 1.5.[3]

Mechai was born in Thailand to a Scottish mother and a Thai father, both of whom were doctors. They met whilst studying in Edinburgh[4] He is one of four children. His younger brother, Sunya, is the founder of the Pattaya International Hospital. One of his two sisters, Sumalee, was formerly a journalist in Bangkok. Mechai was educated at Geelong Grammar School and (The) University of Melbourne in Australia. In the mid-1960s he returned to Thailand and started to work in family planning, emphasizing condoms. In 1973, he left government and founded a non-profit service organization, the Population and Community Development Association (PDA), to continue the work to improve the lives of the rural poor. Among other things, he held condom blowing contests for school children, encouraged taxi cab drivers to hand out condoms to their customers, and founded a restaurant chain called Cabbages and Condoms where condoms, rather than mints or fortune cookies, are given to customers together with the bill.
メチャイ氏は、タイでスコット人の母とタイ人の父の間に生まれ、両方とも医師でした。メチャイ氏はオーストラリアの大学に行き、1960年代半ばに彼はタイに戻り、家族計画の分野で、コンドームを推奨して仕事をするようになりました。1973年に政府を離れ、非営利サービス組織「人口と共同体発展協会(the Population and Community Development Association=PDA)」を設立し、農村貧困者達の生活を向上する仕事を続けました。数ある中で強いてあげるなら、学校の子供達の為にコンドーム膨らましコンテストを開催したり、また、タクシー運転手にコンドームを配るよう奨励したり、キャベツとコンドームというレストラン・チェーン店を開き、そこでお客さんに領収書を渡す時に、ミントや幸運のクッキーなどを渡す代わりにコンドームを渡すようなサービスを始めました。

Mechai served as deputy minister of industry from 1985 to 1986 under prime minister Prem Tinsulanonda. He served as senator from 1987 until 1991. During this time AIDS appeared in Thailand, and he increased his efforts to promote sexual-safety awareness.
A military coup in 1991 installed prime minister Anand Panyarachun; Panyarachun then appointed Viravaidya minister for tourism, information and AIDS. He was able to start a large and quite successful education campaign and served until 1992. In 2004, Mechai again became a senator.

In 1995 he was appointed an Honorary Officer of the Order of Australia, for "service to Australian-Thai relations and contributions to the world AIDS debate".[5]
As of 2007, he continues to oversee rural development and health initiatives as the Chairman of PDA, now the largest NGO in Thailand, with 600 employees and 12,000 volunteers. On May 29, 2007, PDA was awarded the 2007 Bill & Melinda Gates Foundation's Gates Award in recognition of its pioneering work in family planning and HIV/AIDS prevention.[6] This award came with funds of $1,000,000.[7]

An interesting side note is the family planning clinic which openly operates next to the Cabbages and Condoms restaurant. This is one of several places in Bangkok where poor women can receive pregnancy termination, a practice which is legal in the country per Section 305 of the Thailand penal code, but often perceived as illegal.[8][9] The clinic is permitted by the authorities due to the dangers of unsafe abortion by Thai women because of "economic difficulties".[10]
In 2006 he won praise from the toilet industry (but criticism from the retail industry) for proposing that retailers be obliged to build a public toilet for every 10 square metres of retail space.[11]


このエントリーをはてなブックマークに追加 mixiチェック


( ´ ▽ ` )ノ

HIV ウィルスのワクチン
OHSU research helps explain why an AIDS vaccine has been so difficult to develop
URL : http://www.ohsu.edu/xd/about/news_events/news/2012/09-09-ohsu-research-aids-vacci.cfm


For decades, a successful HIV vaccine has been the Holy Grail for researchers around the globe. Yet despite years of research and millions of dollars of investment, that goal has still yet to be achieved. Research by Oregon Health & Science Univ. scientists explains a decades-old mystery as to why slightly weakened versions of the monkey AIDS virus were able to prevent subsequent infection with the fully virulent strain, but were too risky for human use, and why severely compromised or completely inactivated versions of the virus were not effective at all.
何十年にもわたり、HIVのワクチンの作成は世界中の研究家たちが渇望して望んでいるワクチンでした。しかし、何年もの研究や何百万ドルもの投資にも関わらず、そのゴールはまだ達成されませんでした。オレゴン健康科学大学(Oregon Health & Science Univ.=以後、OHSUと省略)の研究家たちによる研究で、何故猿のAIDSウィルスの少し弱化したバージョンが、完全に猛毒なウィルス株に感染するのを防ぐことができて、しかしながら、人間への使用は危険すぎたのか、そして、何故、極度に機能を劣化させた、または、不活性化されたバージョンのウィルスが全く効果がなかったのかについて、何十年もの間疑問とされて来たこの謎を明らかにする説明がされました。
The research was conducted at OHSU’s Vaccine and Gene Therapy Institute and is published online in the journal Nature Medicine.
その研究はOHSUの「ワクチンと遺伝子セラピー研究所」(Vaccine and Gene Therapy Institute)で実施されました。そして、ネイチャー・メディスン(Nature Medicine)のジャーナル紙にオンラインでその結果が投稿さました。
Traditionally, there have been two methods for creating vaccines to combat infectious disease. The first approach utilizes a live, yet weakened strain of the disease in question. This weakened strain is not strong enough to cause illness yet potent enough to activate the immune system so that it can detect and fight a disease if it enters the body in the future. The second approach makes use of a dead form of the disease. As with the other approach, the introduction of the disease in a safe form educates and prepares the body for a possible future invasion.
In the early 1990s, a slightly weakened version of SIV, the monkey counterpart to HIV, was shown to protect monkeys for infection with the fully virulent version, but this weakened version was still able to cause AIDS in some monkeys and the protection was lost if the vaccine virus was further weakened.
“Efforts to develop a live attenuated virus are analogous to the tale of ‘Goldilocks and the Three Bears,’” explained Louis Picker, associate director of the OHSU Vaccine and Gene Therapy Institute.“The field was looking for a vaccine that was ‘not too hot,’ or ‘not too cold,’ but ‘just right.’ The problem was that it appears that weakening a virus to the level that is ‘just right’ is impossible. However, we thought that understanding the mechanism responsible for the protection afforded by the too-dangerous-for-clinical-use attenuated vaccine would allow us to design a vaccine that would be both effective and safe”.
The research shows that the protection is due to anti-viral T cells maintained in lymphoid tissue by persistent live attenuated virus; weakening the virus prevents this persistence and curtails protection. Thus, unlike most vaccines, an effective HIV vaccine might have to persist in the body to be effective.
Picker’s group has developed another persistent virus named cytomegalovirus (CMV) engineered to express SIV or HIV proteins and serve as the transport system (vector) used to raise protective immune responses against these AIDS-causing viruses. In May 2011, the Picker lab published findings that demonstrated how immune responses elicited by their vaccine candidate were able to completely control SIV in a significant number of exposed animals.
CMV is a persistent virus that most people carry, causes few or no symptoms, and elicits very strong cellular responses that are maintained for life. These immune responses are characterized by a type of T cell called an effector memory T cell that has potent anti-viral function and localizes in the same tissues targeted by the AIDS-causing viruses. Picker and his team hypothesize that CMV vector-generated anti-HIV responses would be constantly on the alert for HIV and would be able to intercept and stop HIV infection immediately after exposure.


( ´ ▽ ` )ノ















『男性同型、超リアル形状』とありますが、いろんな形があると思いますので 、メーカーに問い合わせするほうがいいかも・・・


このエントリーをはてなブックマークに追加 mixiチェック










このエントリーをはてなブックマークに追加 mixiチェック

Spray of Hope




Military developing anti-suicide nasal spray as deaths hit record numbers
By Katie Drummond Friday, August 17, 2012

■As the suicide rate among soldiers climbs to the highest levels in history, the Army is hoping Americans might one day treat their mental health woes with a single sniff.


■The Army has just handed a $3 million grant to researchers at the University of Indiana’s School of Medicine for the creation of an anti-suicide nasal spray. The project, to be led by Dr. Michael Kubek, an associate professor of neurobiology, is arguably one of the more unusual military efforts to thwart a record number of suicides among active-duty personnel and veterans.

米軍は三百万ドルの補助金を、抗自殺鼻腔スプレーの開発用として、インディアナ医科大学の研究者達に渡しました。 神経生物学の準教授であるマイケル・キューベック博士によりこのプロジェクトは指揮される予定ですが、現役軍人と退役軍人の間での自殺者数の記録を下げようとするこの試みは、ほぼ間違いなく、これまでに軍が行ってきた更に異常な努力の数々の一つです。

■“Suicide is the toughest enemy I have faced in my 37 years in the Army,” Gen. Lloyd J. Austin III, the Army’s vice chief of staff, said this week in announcing new suicide numbers. Austin is spearheading his service’s efforts to find ways to halt the surge in suicides.

新しい自殺者数を発表するときに、米軍の副参謀長大将ロイド・J・オースチン三世が、「自殺は軍で過去37年間の間に私が遭遇した中で、最強の敵です」と言いました。 オースチンは、自殺の急増を止める方法を見つける為に、自分の職務の努力を注いでいます。

■“That said, I do believe suicide is preventable,” Austin added. “To combat it effectively will require sophisticated solutions aimed at helping individuals to build resiliency and strengthen their life coping skills.”


■According to Kubek and his colleagues, a snort of their suicide-stopping neurochemical — a naturally occurring compound called thyrotropin-releasing hormone, or TRH — could be the solution.


■Suicide among American troops has increased steadily since the start of the wars in Iraq and Afghanistan. In July, the number of suicides among active-duty soldiers reached 26 — more than double the number in June and the highest for any month since the Army began keeping such statistics.


■The Pentagon reported in June that suicides among soldiers have averaged one per day this year, an 18 percent increase in suicides during the same period last year, and have now surpassed the rate of combat fatalities.


■“We’ve known since the 1970s that TRH has antidepressant effects, and it works quite rapidly,” Kubek, whose work has been instrumental in uncovering how TRH impacts the brain, told The Daily. “The bottom-line problem has been figuring out how to get it into the brain.”


■Earlier trials of TRH already showed that boosting an individual’s levels can quickly decrease suicidal ideas, depression and bipolar disorders. But doctors have until now relied on spinal taps to dose patients — because TRH can’t cross the blood-brain barrier by more traditional methods, like pills or injections.


■By harnessing new advancements in nanotechnology, however, Kubek’s research team has now devised nanoparticle drug-delivery systems, designed to dissolve over time inside the brain, that can safely usher TRH across the blood-brain barrier when inserted into the human nasal cavity.


■The nanoparticle breakthrough was enough to convince military brass that Kubek’s nasal spray just might have a shot at preventing suicides. The project’s three-year Army grant will be used to ascertain whether TRH and the drug-delivery systems are safe, and then conduct a clinical trial to “show, in human patients, that this really can save lives,” Kubek said.


■And like a myriad of military medical breakthroughs before it, the spray might one day make it into the hands, and noses, of civilian patients. Already, the National Institute of Mental Health has funded research that used TRH to treat civilians suffering from bipolar disorder and depression. “This is far from a soldiers-only solution,” Kubek said. “Potentially, if this works, we have an entirely new type of pharmacology.”


■Indeed, experts in the realm of civilian mental health said they’re heartened by the research. “This is a brilliant idea,” Dr. Ken Duckworth, medical director for the National Alliance on Mental Illness, told The Daily. “It would solve one of the biggest problems we have with medication used today. It might work, but it doesn’t work fast enough.”

確かに、民間の精神病の領域に携わる専門家達は、その研究により励まされると言いました。「これは、素晴らしいアイデアです」と、「精神病に関する国家同盟(National Alliance on Mental Illness)」の医長を務めるケン・ダックワース医師はデイリー(Daily)に言いました。「この方法は、現在使用されている薬物に関する最も大きな諸問題のひとつを解決するかもしれません。それは効果があるかもしれません、でも、効果が現れるのに時間がかかるでしょう。」

■Should the program succeed, TRH wouldn’t entirely replace traditional antidepressants. Instead, Kubek envisions using it as a rapid-fire prevention tactic among patients in crisis, or immediately after a patient starts taking antidepressants, such as Prozac or Zoloft, which typically take four to six weeks to kick in.


■“The phase directly after starting an antidepressant is very vulnerable time frame in a patient’s life,” he said, adding that patients aged 18-24, like much of the military population, are most at-risk during this period. “The nasal spray would stabilize them right away, while they wait for the [antidepressants] to do their job.”


■Nationwide, suicides are the 10th leading cause of death among adults, according to the Centers for Disease Control and Prevention, and rates continue to hold steady or increase across demographics. “As a public health concern, suicide is something we haven’t had success in addressing,” Duckworth said. “There is a crying need out there for something like this.”



☆ ☆ ☆ (*⌒▽⌒*) ☆ ☆ ☆














このエントリーをはてなブックマークに追加 mixiチェック

このエントリーをはてなブックマークに追加 mixiチェック